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Summary: Water-soluble dinuclear Ru-arene complexes were
synthesized and found to exert promising cytotoxic effects in
human cancer cells, which could be increased to an IC50 of 0.29
µM by increasing the spacer length between the metal centers.
Cytotoxicity could be correlated with lipophilicity (log P Values)
and water solubility. The most potent dinuclear compound, 1,12-
bis{chlorido[3-(oxo-κO)-2-methyl-4-pyridinonato-κO4](η6-p-
isopropyltoluene)ruthenium}dodecane, is at least 2-3 orders
of magnitude more actiVe than the mononuclear analogue
chlorido[3-(oxo-κO)-2-methyl-4-pyronato-κO4](η6-p-isopropyltoluene)-
ruthenium.
Worldwide, about 7.6 million people die from cancer every
year.1 Many common cancer types are still untreatable in an
advanced stage, or therapy is accompanied by serious side
effects and resistance phenomena. The most prominent metal-
based antitumor compound, cisplatin (Figure 1), shows curative
activity in testicular cancer and significant prolongation of life
span in ovarian cancer and to a lesser extent in other tumors.2,3
In recent years, ruthenium complexes have attracted interest
because they exert their tumor-inhibiting effects by a mode of
action different from that of Pt compounds.4 Furthermore, they
show a favorable toxicity profile in clinical trials: In the case
of the ruthenium-indazole complex KP1019 (Figure 1) only
very moderate toxicities were observed in a dose range in which
proteins were on average loaded with one ruthenium species,
which should be sufficient for therapeutic activity.5–7 In the case
of the Ru(imidazole)(dimethylsulfoxide) complex NAMI-A
(Figure 1) the formation of painful blisters was determined as
dose-limiting toxicity.8 Binding to plasma proteins as well as
reduction of RuIII to RuII, resulting in an activation of the metal
center, is regarded as an important step in the mode of action
of KP1019.9 The established Pt anticancer drugs are known to
damage DNA, but it is not regarded as the main target of
NAMI-A and KP1019.8
Furthermore, the use of multinuclear Pt complexes as
chemotherapeutic agents was considered. The trinuclear com-
pound BBR3464 (Figure 1) is 2-3 orders of magnitude more
active than cisplatin in cisplatin-resistant cell lines,10 but nearly
no response was observed in phase II clinical trials.11,12 In
contrast, multinuclear Ru complexes with anticancer activity
are scarcely explored and only a few dinuclear Ru complexes
with tumor-inhibiting properties are known: complexes with
sulfoxide,13 ethylendiamine,14 bisazopyridine,15 porphyrin,16 and
ferrocenyl17 ligands as well as NAMI-A analogous complexes18,19
exhibit relatively low in Vitro activity.
In order to improve the activity of Ru(II)-arene complexes,
which are of current interest as anticancer agents,20–22 two Ru
moieties were coupled with a varying spacer using maltol-derived
bis(3-hydroxy-2-methyl-4-pyridone) ligands (Scheme 1).23,24 Very
recently, the analogous mononuclear Ru-maltol complex was
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shown to exhibit no in Vitro activity up to a concentration of 50
µM in A549 and A2780 cancer cells, and coordination to
9-ethylguanine as a DNA model was established.25
The dinuclear Ru-arene complexes 4a-c were obtained by
reaction between the bis[dichlorido(η6-p-isopropyltoluene)ru-
thenium(II)] 3 and deprotonated bis(3-hydroxy-2-methyl-4-
pyridinon-1-yl)alkanes 2a-c (alkane ) propane 2a, hexane 2b,
dodecane 2c) with yields of 75%, 67%, and 45%, respectively
(Scheme 1). The ligands were prepared by a modified method
of Hider et al.,26 starting from the naturally available synthone
maltol. The benzyl-protected maltol moiety was condensated
with primary aliphatic diamines with varying chain lengths of
three, six, and 12 CH2 groups, and the products were isolated
as HCl-free compounds (in contrast to previous reports26) by
slow crystallization from the reaction mixture or by column
chromatography on silica gel. Finally, ligands 2a-c were
obtained by catalytic hydrogenolysis of the benzyl group.
The complexes were characterized spectroscopically by 1H and
13C NMR and electrospray ionization (ESI) mass spectrometry.
The results corroborate the expected structure: Coordination of the
metal center to the ligand resulted in an upfield shift of ap-
proximately 0.2 ppm for the N-CH proton (at about 7.4 ppm). In
ESI mass spectra in both water and methanol, the most abundant
peaks were assigned to the doubly charged [M - 2Cl]2+ ions.
Furthermore, [M - Cl]+ and [M + Na]+ ions were detected,
containing the highly characteristic isotope pattern for ruthenium
and Ru-Cl species, respectively.
The molecular structure of 4b ·CHCl3 was determined by X-ray
diffraction analysis (Figure 2). The metal centers adopt the pseudo-
octahedral “piano-stool” geometry, with the π-bound arene being
the seat and the σ-bound chlorido and O,O-chelate occupying the
chair’s legs. The Ru-C bond lengths are similar to those reported
for chlorido[3-(oxo-κO)-2-methyl-4-pyridinonato-κO4](η6-p-iso-
propyltoluene)ruthenium(II) (5),25 while the Ru-O and the Ru-Cl
bonds are slightly contracted in 4b (Table 1).
The complexes have two stereogenic ruthenium centers, leading
to a mixture of diastereoisomers. Due to the presence of an axis
of symmetry in the molecules, only one set of signals is observable
in the 1H NMR spectra. In order to study the epimerization of the
dinuclear complexes, 1H NMR measurements were performed for
4b in polar and nonpolar solvents at room temperature (Figure 3).
In the polar solvents D2O and CD3OD, the epimerization takes
place very quickly, and thus only two doublets were detected for
the aromatic protons of the arene group and a single signal for the
isopropyl groups as well as a well-defined triplet for the CH2-N
group (Figures 3a and 3b). These observations may be due to a
fast inversion of the metal center.27 In contrast, spectra in CDCl3
show four doublets for the aromatic protons of the arene group
and two signals for the isopropyl groups as well as two broad
multiplets for the CH2-N groups (Figure 3c). This is in accordance
with previously reported results for similar mononuclear com-
plexes.23
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Figure 1. Structures of cisplatin, carboplatin, oxaliplatin, BBR3464,
KP1019, and NAMI-A.
Scheme 1. Synthesis of the Dinuclear Ruthenium Complexes
4a-c (a, n ) 3, b, n ) 6; c, n ) 12)
Figure 2. Graphical representation of the molecular structure of
the (R,R)-enantiomer of complex 4b in the crystal.
Table 1. Comparison of Selected Bond Lengths of 4b and Chlorido-
[3-(oxo-KO)-2-methyl-4-pyronato-KO4](η6-p-isopropyltoluene)-
ruthenium(II) (5)
bond lengths (Å)/angles (deg)
4b 5a
Ru-Cl 2.4186(10) 2.4329(5)
Ru-O1 2.101(3) 2.1035(13)
Ru-O2 2.074(3) 2.0901(13)
O1-Ru-O2 79.63(11) 78.79(5)
O1-Ru-Cl 83.90(8) 83.42(4)
Cl-Ru-O2 85.11(8) 85.89(4)
a From Peacock et al.25
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The 50% inhibitory concentrations (IC50) of the new complexes
4a-c have been determined in human ovarian carcinoma (A2780)
and colon adenocarcinoma (SW480) cells. IC50 values decrease in
the cell line SW480 from 62 to 26 and 0.29 µM with increasing
chain length of the spacer from three to six and 12 CH2 groups
(Table 2, Figure 4). In A2780 cells, 4a and 4b show similar activity,
but again 4c is the most potent compound. 4c is 1 order of
magnitude more active than cisplatin and equally active as
oxaliplatin in the cell line SW480 and, compared with data from
the literature,28 only 4-5 times less cytotoxic than cisplatin (IC50
) 0.33 µM) and oxaliplatin (IC50 ) 0.40 µM) in the platinum-
sensitive cell line A2780. Furthermore, 4c is 170 times more
cytotoxic in SW480 cells than the mononuclear Ru(III) complex
KP1019, which is currently being studied in clinical trials. Although
methodological differences have to be considered, 4c is 2 orders
of magnitude less cytotoxic than the trinuclear platinum complex
BBR3464 (A2780: IC50 ) 0.01 µM).29 However, coupling three
Pt centers in BBR3464 increases the cytotoxicity only by a factor
of approximately 30, whereas the Ru complexes presented here
are active only when two metals centers are coupled; that is, the
mononuclear analogue is not cytotoxic.
The spacer-length-dependent cytotoxicity in cancer cells impli-
cates a correlation with the lipophilicity of the compounds, which
is an important factor for anticancer drugs, since hydrophobic
compounds can cross cell membranes easier than hydrophilic
ones.30 The lipophilic character of 4a-c was investigated by
determination of the n-octanol/water partition coefficient, log P,
applying the shake flask method.31 Ruthenium contents in the
aqueous and octanol phases were quantified by ICP-MS and UV/
vis, respectively, and both methods lead to essentially identical
results. Log P values in the range from -1.33 to -0.56 were
obtained for the dinuclear compounds and correlate with the length
of the spacer linking the pyridinone moieties. The solubility of the
dinuclear compounds in water reflects the n-octanol/water partition
coefficients. With increasing chain length of the complexes from
three to six and 12 CH2 groups, the solubility in water decreases
from about 13.4 to 3.4 and 0.5 mM, respectively, also correlating
with the in Vitro activity.
Summarizing, coupling more than one metal center with the
aim of improving the anticancer activity of Ru(II)-arene
metallodrugs led to the development of complexes with high
activity in human tumor cell lines. Notably, not only an additive
effect of the analogous mononuclear complexes but a synergistic
effect in two cell lines was observed, being of extraordinary
dimension in SW480 cells for Ru compounds. For the series of
dinuclear compounds, a spacer-length-dependent order of in
Vitro activity was found, allowing modulation of both anticancer
activity and lipophilicity. However, the mode of action is not
absolutely clear yet, and several targets, including DNA but
also proteins, are conceivable.
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Figure 3. 1H NMR spectra of 4b in (a) CD3OD, (b) D2O, and (c)
CDCl3.
Table 2. IC50 Values of the Complexes 4a-c in A2780 and SW480
Cells in Comparison to the Pt Complexes Cisplatin, Oxaliplatin,
Carboplatin, and BBR3464 and the Ru Compounds KP1019 and the
4a-c Analogous Mononuclear Maltol Complex 5
IC50/µM
compound A2780 SW480
4a 25 ( 2 62 ( 14
4b 30 ( 6 26 ( 8
4c 1.5 ( 0.3 0.29 ( 0.05
5 >10025 >100
cisplatin 0.33 ( 0.0428 4.5 ( 1.7
carboplatin 61 ( 10
oxaliplatin 0.40 ( 0.1228 0.30 ( 0.08
BBR3464 0.0129
KP1019 49 ( 11
Figure 4. Concentration-effect curves of dinuclear Ru(II)-arene
complexes 4a-c, obtained by the MTT assay in SW480 cells.
Values are means ( standard deviations from at least three
independent experiments.
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